KURA
Kura OncologyANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
KOMZIFTI's first full quarter showed commercial traction, payer coverage is already broad, and the cash/collaboration package appears sufficient to get to key frontline Phase 3 data. If 2026 readouts reinforce the safety/combinability story and adoption broadens, the stock can move from a launch story toward a platform thesis.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +28.0.
What can break
Commercial uptake is still early, so the launch ramp has to persist beyond the first full quarter to matter.
Momentum
80
Value
53
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.00 · Bull $32.00 · Bear $4.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $32.45
Why
Momentum80 · Δ7d +3.1
Value53 · Δ7d +0.4
Sentiment100 · Δ7d +28.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
80
34% active weight
Current posture
7d trendFlat
Δ7d
+3.1
Δ21d
+19.7
Value
53
32% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.3
Sentiment
100
33% active weight
Current posture
7d trendImproving
Δ7d
+28.0
Δ21d
+7.1
Why this grade
Composite grade A. Momentum 80.0 / Value 52.9 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$802.08M
Beta
0.24
Shares Out
87.02M
P/E (TTM) · Derived
-4.6
P/S (TTM)
7.98
P/FCF (TTM)
9.99
Rev YoY
-
EPS YoY
-35.2%
Gross Margin
-
Op Margin
-230.5%
Net Debt
-$717.87M
Current Ratio
5.12
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology